Literature DB >> 18199106

Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4.

Aristeidis Stavroulopoulos1, Christine J Porter, Simon D Roe, David J Hosking, Michael J D Cassidy.   

Abstract

AIM: Low vitamin D status is associated with secondary hyperparathyroidism and increased bone turnover in the general population and can aggravate the hyperparathyroidism of chronic kidney disease (CKD) patients. It is also correlated to low bone mineral density (BMD), but this correlation is less clear in CKD patients. Aims of our study were to investigate these associations in CKD stages 3 and 4 patients, and to identify significant predictors of BMD in this population.
METHODS: Serum 25-hydroxyvitamin D (25OHD) levels, BMD at the femur and radius, and bone mineral metabolism parameters were measured in 89 CKD stages 3 and 4 patients. Vitamin D status was defined according to the NKF/KDOQI guidelines.
RESULTS: Mean 25OHD levels were 53.8+/-32.1 nmol/L and correlated to the severity of proteinuria. Thirty-five patients (39%) had vitamin D insufficiency, 29 (33%) had vitamin D deficiency and five (6%) had severe deficiency. Of the 89 patients, two had osteoporosis and 31 had osteopenia either at femur or radius. Independent predictors for the total femur BMD were the intact parathyroid hormone (iPTH) levels and the body mass index (BMI). For the total radius BMD, independent predictor was only the BMI. Serum 25OHD levels were not directly associated with BMD, but they were independent predictors of iPTH.
CONCLUSION: Vitamin D insufficiency and deficiency are very common in CKD stages 3 and 4 population and may indirectly affect, via effects on iPTH, the BMD of these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199106     DOI: 10.1111/j.1440-1797.2007.00860.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  17 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

2.  Ethnic differences in 25-hydroxyvitamin D levels and response to treatment in CKD.

Authors:  Iris Sanchez; Roberto Mangoo-Karim; Jason R Stubbs; George P Yanev; James B Wetmore
Journal:  Int Urol Nephrol       Date:  2012-05-30       Impact factor: 2.370

3.  Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients.

Authors:  Jong Chan Park; Csaba P Kovesdy; Uyen Duong; Elani Streja; Mehdi Rambod; Allen R Nissenson; Stuart M Sprague; Kamyar Kalantar-Zadeh
Journal:  Hemodial Int       Date:  2010-03-24       Impact factor: 1.812

4.  Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study.

Authors:  Jeffrey R Curtis; Susan K Ewing; Douglas C Bauer; Jane A Cauley; Peggy M Cawthon; Elizabeth Barrett-Connor; Elizabeth M Haney; Areef Ishani; Serge Cremers; Eric Orwoll
Journal:  J Clin Endocrinol Metab       Date:  2012-03-22       Impact factor: 5.958

Review 5.  Vitamin D in organ transplantation.

Authors:  E M Stein; E Shane
Journal:  Osteoporos Int       Date:  2011-01-05       Impact factor: 4.507

6.  Vitamin D deficiency is common in children and adolescents with chronic kidney disease.

Authors:  Heidi J Kalkwarf; Michelle R Denburg; C Frederic Strife; Babette S Zemel; Debbie L Foerster; Rachel J Wetzsteon; Mary B Leonard
Journal:  Kidney Int       Date:  2011-12-28       Impact factor: 10.612

7.  Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.

Authors:  S Geng; Z Kuang; P L Peissig; D Page; L Maursetter; K E Hansen
Journal:  Osteoporos Int       Date:  2019-05-31       Impact factor: 4.507

8.  Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States.

Authors:  Oluwatoyin M Adeyemi; Denis Agniel; Audrey L French; Phyllis C Tien; Kathleen Weber; Marshall J Glesby; Maria C Villacres; Anjali Sharma; Daniel Merenstein; Elizabeth T Golub; William Meyer; Mardge Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

9.  A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.

Authors:  Sharon M Moe; Akber Saifullah; Robert E LaClair; Sohail A Usman; Zhangsheng Yu
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

10.  Severe vitamin D deficiency among heart and liver transplant recipients.

Authors:  Emily M Stein; Adi Cohen; Matthew Freeby; Halley Rogers; Shannon Kokolus; Vanessa Scott; Donna Mancini; Susan Restaino; Robert Brown; Donald J McMahon; Elizabeth Shane
Journal:  Clin Transplant       Date:  2009-04-23       Impact factor: 2.863

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.